View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Mercury Systems to Report Third Quarter Fiscal Year 2025 Financial Res...

Mercury Systems to Report Third Quarter Fiscal Year 2025 Financial Results on May 6, 2025 ANDOVER, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Mercury Systems Inc. (NASDAQ: MRCY, ), a technology company that delivers mission-critical processing power to the edge, will release its third quarter fiscal year 2025 financial results after the market close on Tuesday, May 6, 2025. Management will host a conference call and simultaneous webcast at 5:00 p.m. ET on the same day to discuss Mercury's quarterly financial results, business highlights, and outlook. In addition, Company representatives m...

 PRESS RELEASE

Mercury and Cicor Group Create Long-Term Strategic Business Relationsh...

Mercury and Cicor Group Create Long-Term Strategic Business Relationship In Support of European Defense ANDOVER, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Mercury Systems, Inc. (NASDAQ: MRCY, ), a technology company that delivers mission-critical processing power to the edge, today announced it has entered into a strategic supply agreement under which Cicor Group (SIX Swiss Exchange: CICN) will acquire a manufacturing operation in Plan-Les-Ouates, Switzerland, and supply Mercury with electronic products over the next five years. Mercury Mission Systems International S.A. is a leading p...

 PRESS RELEASE

Solésence Announces Uplisting to Nasdaq

Solésence Announces Uplisting to Nasdaq Trading set to begin Tuesday, April 8 under new ticker “SLSN” ROMEOVILLE, Ill., April 07, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (OTCQB: NANX), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that it has received approval from the Listing Qualifications Department of Nasdaq to transfer its listing to the Nasdaq Capital Market. The Company’s securities will be uplisted to Nasdaq at the opening of business on Tuesday, April 8, 2025. Prior to listing on Nasdaq, the Company’s shares t...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: March 29, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Solésence Reports Record Fourth Quarter and Full-Year 2024 Financial R...

Solésence Reports Record Fourth Quarter and Full-Year 2024 Financial Results Fourth quarter revenue increased 58% to a record $12.6 million Full Year 2024 revenue increased 40% to a record $52.3 million ROMEOVILLE, Ill., March 26, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (OTCQB: NANX), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the fourth quarter and year ended December 31, 2024.    Recent Highlights and Accomplishments Company rebranded as Solésence, Inc., marking a new era of innovation, se...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: March 22, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Solésence To Report Fourth Quarter and Full Year 2024 Financial Result...

Solésence To Report Fourth Quarter and Full Year 2024 Financial Results and Host a Conference Call ROMEOVILLE, Ill., March 20, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (OTCQB: NANX), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that the Company will report results for the fourth quarter and full year 2024 after the market close on Wednesday, March 26, 2025, and host a conference call and webcast on Thursday, March 27. Fourth Quarter 2024 Conference Call Details Date / Time: Thursday, March 27, 2025 - 7:00 a.m. CDT, 8:...

Hillenbrand Inc: 1 director

A director at Hillenbrand Inc bought 8,857 shares at 25.189USD and the significance rating of the trade was 61/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...

 PRESS RELEASE

Sana Biotechnology Reports Fourth Quarter and Full Year 2024 Financial...

Sana Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates Announced positive preliminary 12-week clinical results, building on already released 4-week results, of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression overcome autoimmune and allogeneic immune recognition, function, and persist with stable C-peptide production post-transplant Enrolling patients in the GLEAM trial for SC291 in B-cell mediated autoimmune diseases and VIVID trial for SC262 in relapsed/refractory B-ce...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Research Team ACF
  • Research Team ACF

ACF Thematic Research Regenerative Medicine Diabetes Treatment & Innov...

Diabetes mellitus, Type 1 (T1D) and Type 2 (T2D, 85-90% of cases), is a USD ~75bn global therapy market. Global economic costs of diabetes may exceed USD1 trn today and USD 450bn in the US, suggesting a pressing global health challenge. Diabetes is a chronic metabolic disorder characterized by high blood sugar levels. In 2024, consensus global estimates suggested there were ~800m adult diabetes sufferers. In 2021, according to the IDF there >530m sufferers globally. For 2027E we modestly forecas...

 PRESS RELEASE

Solésence Wins Best Prestige Finished Formula at the 2025 Cosmetics & ...

Solésence Wins Best Prestige Finished Formula at the 2025 Cosmetics & Toiletries Allē Awards, Marking Third Consecutive Win ROMEOVILLE, Ill., March 13, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (OTCQB: NANX), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that their market-ready product, ™ technology, has been named the winner for best prestige finished formula at the 2025 Cosmetics & Toiletries (C&T) Allē Awards. The award, which recognizes the company’s achievements across criteria including novelty and practicality, su...

 PRESS RELEASE

Solésence Launches New Investor Relations Website

Solésence Launches New Investor Relations Website ROMEOVILLE, Ill., March 12, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (OTCQB: NANX), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced the launch of its new investor relations website. Designed as a centralized hub and resource, beauty industry investors and partners can access financial information about the company and its innovative skin health solutions at . The launch of the new website comes on the heels of Nanophase Technologies Corporation announcing it is rebranding ...

 PRESS RELEASE

Nanophase Technologies Rebrands as Solésence, Elevating the Future of ...

Nanophase Technologies Rebrands as Solésence, Elevating the Future of Skin Health ROMEOVILLE, Ill., March 07, 2025 (GLOBE NEWSWIRE) -- Nanophase Technologies Corporation (OTCQB: NANX), a leader in mineral-based and scientifically-driven health care solutions across beauty and life science categories, today announced its rebranding as Solésence, Inc., marking a new chapter in its commitment to innovation, self-expression, and inclusivity in skin health. The rebranding underscores the success of the company’s beauty science platform, which has revolutionized mineral-based sun and environ...

 PRESS RELEASE

Sana Biotechnology to Present at the Cowen 45th Annual Health Care Con...

Sana Biotechnology to Present at the Cowen 45th Annual Health Care Conference SEATTLE, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the Cowen 45th Annual Health Care Conference at 3:10 p.m. ET on Monday, March 3, 2025. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer. The webcast will be accessible on the Investor Relations page of Sana’s website at ....

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: February 15, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: February 10, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Research Team ACF
  • Research Team ACF

Sana Biotechnology (SANA) Core Investment Case 05022025

Sana Biotechnology (NasdaqGS:SANA) is a well-funded cell and gene therapy innovator. Its therapies address significant unmet needs across oncology, central nervous system (CNS) disorders, and rare genetic diseases. Leveraging IP protected platform technologies, SANA is developing a robust pipeline of allogeneic cell therapies, in vivo gene editing and hypoimmune solutions, that might revolutionize treatment paradigms. SANA has a potentially transformative approach to cell and gene therapy via it...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch